Third View Private Wealth
VRTX icon

Third View Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Third View Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.42M Buy
18,009
+143
+0.8% +$73.2K 1.11% 19
2026
Q2 		$8.87M Buy
17,866
+965
+6% +$428K 1.09% 20
2026
Q1 		$7.55M Buy
16,901
+1,184
+8% +$552K 1.03% 22
2025
Q4 		$7.13M Buy
+15,717
New +$6.77M 0.96% 23

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Third View Private Wealth's VRTX Position: Q3 2026 in Review

Third View Private Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 0.8% in Q3 2026, buying an estimated $73.2K and bringing the position to 18,009 shares worth $9.42M. The position accounts for 1.11% of the portfolio, ranked #19.

Third View Private Wealth first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. 992 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Third View Private Wealth held 18,009 shares of Vertex Pharmaceuticals worth $9.42M as of Q3 2026.
  • Third View Private Wealth bought 143 Vertex Pharmaceuticals shares in Q3 2026, an estimated $73.2K.
  • Vertex Pharmaceuticals made up 1.11% of Third View Private Wealth's portfolio in Q3 2026, its #19 holding.
  • Third View Private Wealth first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 992 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Third View Private Wealth's 13F filing for Q3 2026, filed 30 Oct 2026.